Indication
For the treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components.

Medicine details

Medicine name:
bictegravir-emtricitabine-tenofovir alafenamide (Biktarvy)
SMC ID:
SMC2093
Pharmaceutical company
Gilead Sciences Ltd
BNF chapter
Infections
Submission type
Full submission
Status
Advice due date:
10 September 2018
SMC meeting date:
07 August 2018
Patient group submission deadline:
02 July 2018